Alnylam Pharmaceuticals (ALNY)
(Real Time Quote from BATS)
$270.92 USD
-5.41 (-1.96%)
Updated Sep 20, 2024 11:24 AM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 11/7/24 |
---|---|
Current Quarter | -0.50 |
EPS Last Quarter | 0.56 |
Last EPS Surprise | 175.68% |
ABR | 1.70 |
Earnings ESP
|
-23.84% |
---|---|
Current Year | -0.63 |
Next Year | -0.26 |
EPS (TTM) | 0.45 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 530.57M | 548.19M | 2.23B | 2.38B |
# of Estimates | 11 | 11 | 11 | 12 |
High Estimate | 583.80M | 602.00M | 2.32B | 2.68B |
Low Estimate | 502.13M | 520.50M | 2.16B | 2.15B |
Year ago Sales | 750.53M | 439.72M | 1.83B | 2.23B |
Year over Year Growth Est. | -29.31% | 24.67% | 21.71% | 6.75% |
Earnings Estimates
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.50 | -0.44 | -0.63 | -0.26 |
# of Estimates | 9 | 9 | 8 | 9 |
Most Recent Consensus | -0.69 | -0.59 | -0.89 | -1.79 |
High Estimate | -0.19 | -0.04 | -0.28 | 1.63 |
Low Estimate | -0.71 | -0.67 | -0.97 | -2.16 |
Year ago EPS | 1.15 | -1.10 | -3.52 | -0.63 |
Year over Year Growth Est. | -143.48% | 60.00% | 82.10% | 58.31% |
Agreement - Estimate Revisions
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 2 | 2 | 2 | 1 |
Up Last 60 Days | 8 | 7 | 8 | 6 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 1 |
Down Last 60 Days | 1 | 2 | 0 | 3 |
Magnitude - Consensus Estimate Trend
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.50 | -0.44 | -0.63 | -0.26 |
7 Days Ago | -0.50 | -0.44 | -0.63 | -0.26 |
30 Days Ago | -0.52 | -0.47 | -1.03 | -0.26 |
60 Days Ago | -0.70 | -0.58 | -2.16 | -0.63 |
90 Days Ago | -0.74 | -0.64 | -2.35 | -0.83 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (9/2024) |
Next Qtr (12/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.62 | -0.51 | -0.72 | -0.82 |
Zacks Consensus Estimate | -0.50 | -0.44 | -0.63 | -0.26 |
Earnings ESP | -23.84% | -15.15% | -15.50% | -216.74% |
Surprise - Reported Earnings History
Quarter Ending (6/2024) |
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | 0.56 | -0.16 | -1.10 | 1.15 | NA |
Estimate | -0.74 | -0.75 | -1.20 | -1.61 | NA |
Difference | 1.30 | 0.59 | 0.10 | 2.76 | 1.19 |
Surprise | 175.68% | 78.67% | 8.33% | 171.43% | 108.53% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more